Kidsland International Holdings Limited 凱知樂國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代 號：2122） （以 下 稱「公 司」） 提 名 委 員 會－職 權 範 圍 書 1. 成 員 2. 秘 書 3. 會 議 3.1 提 名 委 員 會 成 員 可 以 在 有 需 要 的 情 況 下 於 任 何 時 間 召 開 會 議。提 名 委 員 會 任 何 成 員 或 秘 書 可 要 求 舉 行 會 議。 – 1 – 1.1 提 名 委 員 會（「提名委員會」）須 由 公 司 董 事 會（「董事會」）委 任，且 提 名 委 員 會 的 大 多 數 成 員 應 為 獨 立 非 執 行 董 事，至 少 一 名 成 員 為 不 同 性 別。成 員 須 由 董 事 委 任。 1.2 提 名 委 員 會 之 主 席 應 由 董 事 會 委 任，並 須 由 董 事 會 主 席 或 委 員 會 中 之 獨 立 非 執 行 董 事 擔 任。 1.3 提 名 委 員 會 成 員 的 委 任 年 期 由 董 事 會 於 委 任 時 決 定。 2.1 提 名 委 員 會 之 秘 ...

下 文 載 列 凱 知 樂 國 際 控 股 有 限 公 司 董 事 會（「董事會」）成 員。 執行董事 非執行董事 李澄曜先生 （主 席） 杜平先生 仲梅女士 Kidsland International Holdings Limited 凱知樂國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代 號：2122） 董事名單及其角色及職能 審核委員會 獨立非執行董事 鄭毓和先生 黃嘉純先生 Albert Thomas da Rosa, Junior先 生 鄭毓和先生 （主 席） 黃嘉純先生 Albert Thomas da Rosa, Junior先 生 薪酬委員會 黃嘉純先生 （主 席） 鄭毓和先生 李澄曜先生 提名委員會 李澄曜先生 （主 席） 鄭毓和先生 黃嘉純先生 仲梅女士 Albert Thomas da Rosa, Junior先 生 香 港，2025年8月27日 董 事 會 下 設 三 個 委 員 會。該 等 委 員 會 成 員 及 各 董 事 會 成 員 所 擔 任 的 職 位 載 列 如 下： ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 凱 知 樂 國 際 控 股 有 限 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，獨 立 非 執 行 董 事Albert Thomas da Rosa, Junior先 生（「da Rosa先 生」）已 獲 委 任 為 董 事 會 提 名 委 員 會 成 員，自2025年8月27日 起 生 效。 董事會謹此熱烈歡迎da Rosa先 生 在 董 事 會 擔 任 其 他 職 務。 Kidsland International Holdings Limited 凱知樂國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代 號：2122） 提名委員會的組成變更 承董事會命 凱知樂國際控股有限公司 主 席、行 政 總 裁 兼 執 行 董 事 李澄曜 香 港，2025年8月27日 截 至 本 公 告 日 期，董 事 會 成 員 包 括 執 ...

格隆汇8月15日丨凯知乐国际(02122.HK)宣布，谨订于2025年8月27日（星期三）举行本公司董事会会 议，旨在（其中包括）考虑及批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩以供发 布，以及考虑宣派中期股息（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Kidsland International Holdings Limited 凱知樂國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代 號：2122） 董事會會議日期 凱 知 樂 國 際 控 股 有 限 公 司（「本公司」）宣 佈，謹 訂 於 二 零 二 五 年 八 月 二 十 七 日（星 期 三）舉 行 本 公 司 董 事 會（分 別 為「董 事」及「董事會」）會 議，旨 在（其 中 包 括）考 慮 及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績 以 供 發 佈，以 及 考 慮 宣 派 中 期 股 息（如 有）。 代 表 凱知樂國際控股有限公司 於 本 公 告 日 期，董 事 會 成 員 包 括 執 行 董 事 李 澄 曜 先 生（主 席 兼 行 政 總 裁）及 仲 梅 女 士；非 執 行 董 事 杜 平 先 生； ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 公司名稱: 凱知樂國際控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02122 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 48,800,000,000 | HKD | | 0.01 | HKD | | 488,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 48,800,000,000 | HKD | | 0.01 | HKD | | 488,000,000 | | ...

Core Insights - The Chinese life sciences industry is undergoing rapid transformation driven by policy relaxation, technological innovation, the rise of domestic companies, and the development of specialized real estate ecosystems [9][18][39] - The report "Trends in China's Life Sciences" provides a comprehensive overview of current market dynamics, regulatory changes, and future development directions [9] Policy Environment - Nationally, China has relaxed foreign investment restrictions in gene and cell therapy, allowing foreign-owned hospitals in major cities [10][20] - Local governments in cities like Beijing, Shanghai, and Shenzhen are offering targeted subsidies and fast-track approval processes to support biotechnology development [10][27] Industry Innovation and Company Growth - Chinese life sciences companies are shifting from generic drug production to innovative therapies, with firms like CanSino Biologics and BeiGene leading in CAR-T cell therapy and bispecific antibodies [11][29] - These companies are attracting international investment and licensing agreements, enhancing China's position in the global life sciences sector [11][39] Real Estate Development and Regional Hubs - Innovation hubs such as Suzhou BioBay and Shanghai Zhangjiang Hi-Tech Park provide end-to-end support, including shared laboratories and GMP-compliant facilities [12][35] - Second-tier cities like Chengdu and Ningbo are emerging as new growth centers, expanding the life sciences ecosystem [12][35] Owner Perspective - Real estate developers are adapting to industry-specific needs through light-asset models and flexible leasing arrangements [14][45] - While first-tier cities face saturation, demand remains robust in central and western regions, with a focus on sustainability and compliance [14][45] Tenant Perspective - Life sciences tenants are responding to regulatory reforms and increased compliance requirements, seeking flexibility and proximity to talent and infrastructure [15][46] - The highest demand is for GMP-certified laboratories and modular production facilities, emphasizing location advantages and sustainability certifications [15][46] Future Outlook - Growth opportunities lie in AI-driven drug development, personalized medicine, and advanced therapies, supported by government policies [16][39] - Life sciences real estate is evolving from generic parks to specialized, digitally-enabled facilities with high compliance and flexibility [16][39]

港股医疗健康板块也逐渐开始回暖，更多企业涌向港交所申请IPO，其中不乏独角兽级别的企业——去 年12月，微医时隔三年重启IPO；今年5月，英矽智能三度递表；今年6月，镁信健康也赴港申请IPO。 过去十年间，中国医疗投资市场经历了巨大的起伏，从2015年行业融资额暴增，开启医疗投资的"元 年"，到2021年达到3800余亿元的融资峰值，而后行业又进入沉寂。 在这一波波投资热潮里，医疗健康行业里产生了数百家估值超十亿美元的医疗独角兽，分布在数字医 疗、AI制药、手术机器人、互联网医院、慢病管理平台等各个领域。大家都一度风华正茂，头顶着技 术创新、政策蓝海或美好的商业预期等各种光环，在不断加注的融资中走到独角兽的体量。幸运几乎是 这一批医疗独角兽的共同特征，巨大的外部机遇让它们以极低的时间成本将成就最大化。 但也正是在这一轮又一轮的资本热潮中，行业的"堰塞湖"悄然形成：高估值、大投入、慢转化。在漫漫 创业长路里，许多项目因为不确定的商业回报兑现、冗长的客户转化周期与故事的一再切换，让公司处 于持续亏损，通过上市来兑现"估值"变得遥遥无期，甚至要面临生存危机。医疗行业的一级市场漂悬着 众多的"梦"，太多创始人、高管团 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company faced challenges but identified clearer trends and changing consumer demands, with some brands achieving double-digit growth while others struggled [5]. - The company reported a significant increase in revenue, achieving a total of $1.2 billion, representing a 15% year-over-year growth [1]. - Revenue decreased by 15.7% from approximately RMB 1,155.7 million to approximately RMB 974.5 million due to weak market sentiment and consumer spending downgrade [28]. - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 10% to $1.32 billion [3]. - New product launches are expected to contribute an additional $200 million in revenue over the next fiscal year [4]. - Market expansion plans include entering three new countries, which are projected to add $300 million in revenue over the next two years [6]. - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year [9]. - The gross profit margin remained stable at 29.3% compared to 29.8% in the previous period [28]. - The company recorded a loss of approximately RMB 202.4 million for the period, slightly improved from a loss of approximately RMB 210.9 million in the previous period [53]. Cost Management and Efficiency - Operating costs were reduced by 13.9% compared to the previous fiscal year, with inventory decreasing by approximately RMB 72.5 million and inventory turnover days reduced by 20 days [7]. - Operating expenses were reduced by 5%, resulting in a more efficient cost structure [10]. - The cash conversion cycle improved from 131 days to 97 days, indicating better efficiency in converting inventory investments into cash [55]. - Total sales, distribution, general and administrative expenses decreased by 13.9% from approximately RMB 539.9 million to approximately RMB 465.1 million [28]. Strategic Partnerships and Market Expansion - The partnership with Spin Master resulted in nearly doubling sales in 2024, while collaboration with Card Game achieved approximately 40% sales growth, and Jellycat saw a 55% increase, contributing to a total growth of 94% from these brands, accounting for nearly 12% of total business in mainland China [6]. - A new agreement with Spin Master will commence in 2025 for the distribution of Paw Patrol toys in Hong Kong, Macau, and Taiwan, indicating a strategic focus on expanding market presence [8]. - The overall strategy emphasizes collaboration with leading brands and the development of proprietary products to expand the older children's business segment [10]. Research and Development - The company is investing $50 million in research and development for new technologies aimed at enhancing user experience [5]. - Plans to leverage artificial intelligence to improve operational efficiency and explore new business opportunities are in place [10]. Employee Management and Workforce - As of December 31, 2024, the group had approximately 1,100 employees in mainland China, Hong Kong, and Macau, a decrease from 1,300 employees as of December 31, 2023 [127]. - The overall employee turnover rate is 55.0%, with 598 employees leaving the company during the reporting period [192]. - The company has implemented a comprehensive employee management policy covering recruitment, performance evaluation, training, and compensation [185]. - The company provides various employee benefits, including social and medical insurance, maternity leave, and family-friendly policies [195]. Environmental, Social, and Governance (ESG) Initiatives - The company has established compliance procedures to ensure adherence to applicable environmental laws and regulations [84]. - The group is committed to integrating sustainability into its business operations and has established an environmental, social, and governance (ESG) framework [141]. - The company aims to achieve carbon neutrality and has implemented strict administrative policies to manage emissions from its office operations [165]. - The company has identified 21 key ESG topics that impact its operations, including emissions management, waste management, and employee welfare [157]. - The company encourages resource efficiency and waste reduction through various green office initiatives, aiming for a sustainable operational model [174]. Shareholder and Capital Management - The company has issued 800,000,000 ordinary shares with a par value of HKD 0.01, with no changes in share capital during the reporting period [64]. - The board has resolved not to recommend any dividend for the year, consistent with the previous year [77]. - The company has adopted a dividend policy aimed at providing sustainable returns to shareholders while retaining earnings for future growth opportunities [80]. - The company’s largest shareholder, Asian Glory, holds approximately 53.15% of the shares, which is controlled by Mr. Li Chengyao [98]. Compliance and Governance - The company confirms compliance with the listing rules regarding all ongoing related party transactions [120]. - The non-competition agreement established on October 25, 2017, has been adhered to by the controlling shareholders [123]. - The company has maintained a minimum public float of 25% throughout the year and as of the report date [134].

Revenue Performance - The group's revenue decreased by 15.7% to approximately RMB 974.5 million from RMB 1,155.7 million in the previous period[3]. - The company's revenue decreased by 15.7% from approximately RMB 1,155.7 million to approximately RMB 974.5 million due to weak market sentiment and consumer spending[20]. - Total revenue for the year ended December 31, 2024, reached RMB 3,974,488 thousand, a significant increase from RMB 1,155,738 thousand in 2023[41]. - For the year ending December 31, 2024, the company reported a total revenue of RMB 974,488,000, a decrease from RMB 1,155,738,000 in 2023, reflecting a decline of approximately 15.7%[75]. Profitability and Loss - The group recorded a net loss of approximately RMB 202.4 million after tax, slightly improved from RMB 210.9 million in the previous period[3]. - The company recorded a net loss of approximately RMB 202.4 million, an improvement from the previous period's loss of approximately RMB 210.9 million[31]. - Net loss for the year was RMB 202,409 thousand, slightly better than the net loss of RMB 210,945 thousand in 2023, showing a reduction of approximately 4%[41]. - The company recorded a net loss of RMB 9,098,000 in 2024, compared to a net loss of RMB 7,708,000 in 2023, indicating a worsening financial position[77]. Expenses and Cost Management - Total sales, distribution, general, and administrative expenses decreased by 13.9% to approximately RMB 465.1 million from RMB 539.9 million in the previous period[3]. - The company is implementing cost-saving measures to manage sales and distribution expenses, as well as general and administrative costs, to enhance operational cash flow[54]. Inventory and Cash Management - Inventory turnover days decreased to 141 days, and cash conversion cycle improved to 97 days from 161 days and 131 days in the previous period respectively[3]. - The group reduced inventory by approximately RMB 72.5 million, resulting in a 20-day reduction in inventory turnover days[7]. - The cash conversion cycle decreased from 131 days in the previous period to 97 days in the reporting period[33]. Financial Position and Liabilities - Total assets decreased to RMB 454,217 thousand in 2024 from RMB 580,753 thousand in 2023, a decline of about 22%[42]. - The company's total liabilities decreased to RMB 540,117 thousand in 2024 from RMB 693,538 thousand in 2023, indicating a decline of approximately 22%[42]. - As of December 31, 2024, the company's net current liabilities amounted to RMB 13,523,000, and total net liabilities were RMB 83,900,000[49]. - The group had no significant contingent liabilities as of December 31, 2024[38]. Capital Expenditures and Financing - Capital expenditures for the reporting period amounted to approximately RMB 16.5 million, primarily for store renovations, compared to RMB 14.3 million in the previous period[34]. - The company has extended and increased its loan financing from HKD 150,000,000 (approximately RMB 135,930,000) to HKD 250,000,000 (approximately RMB 231,500,000), with HKD 100,000,000 (approximately RMB 91,708,000) remaining as undrawn financing as of December 31, 2024[54]. - A loan capitalization agreement was established for HKD 100,000,000 (approximately RMB 92,600,000) to improve the financial position and liquidity of the group[50]. Governance and Compliance - The company has adopted the corporate governance code as per the listing rules and has complied with all mandatory disclosure requirements during the reporting period[109]. - The audit committee, consisting of three independent non-executive directors, has reviewed and confirmed the annual performance of the group[111]. - The financial figures in the preliminary announcement have been verified by the auditor, Daxin CPA, ensuring consistency with the audited financial statements[112]. Market Presence and Business Development - The group expanded its Hall One stores for older children to four additional cities, enhancing its market presence[6]. - The group established a new business unit focused on developing the older children's market, integrating more products into Kidsland and FAO stores[6]. - The company is expanding new sales channels and product lines to boost sales and attract a diverse range of new customers[54]. Employee and Compensation - The total number of employees decreased to approximately 1,100 as of December 31, 2024, down from about 1,300 in the previous year[104]. - The total compensation for internal and external employees was approximately RMB 95.2 million and RMB 71.9 million, respectively, compared to RMB 104.6 million and RMB 82.6 million in the previous period[104].